March 2005 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
86 citations
,
June 2018 in “Cochrane library” This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.
66 citations
,
January 2010 in “Journal of The American Academy of Dermatology” This study reported that mycophenolate mofetil was effective in reducing signs and symptoms of active lichen planopilaris in 83% of patients who had failed multiple prior treatments.
54 citations
,
May 2019 in “Multiple Sclerosis and Related Disorders” This study found that azathioprine may improve relapses and disability in patients with neuromyelitis optica spectrum disorder but is associated with higher adverse events compared to mycophenolate mofetil.
26 citations
,
March 2015 in “American journal of clinical dermatology” This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.